Phase 1/2 study of PARG inhibitor ETX-19477 in patients with advanced solid malignancies

Disease:

Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer

Study phase:

Phase I

Physician name:

Timothy Yap

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-364-0962